Trevi Therapeutics, Inc. Common Stock (TRVI) is a publicly traded Healthcare sector company. As of May 21, 2026, TRVI trades at $13.88 with a market cap of $1.91B and a P/E ratio of -29.24. TRVI moved +4.83% today. Year to date, TRVI is +22.18%; over the trailing twelve months it is +114.53%. Its 52-week range spans $2.36 to $16.12. Analyst consensus is strong buy with an average price target of $24.50. Rallies surfaces TRVI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Trevi Therapeutics, Inc. Common Stock (TRVI) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. TRVI moved +4.83% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $13.88 |
| Market Cap | $1.91B |
| P/E Ratio | -29.24 |
| EPS | $-0.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.12 |
| 52-Week Low | $2.36 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-47.91M |
| Gross Margin | 0.00% |
8 analysts cover TRVI: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.50.